A case of SDRIFE (symmetric drug-related intertriginous and flexural exanthema) associated with denosumab
	    		
		   		
		   			
		   		
	    	
    	 
    	10.4168/aard.2025.13.1.39
   		
        
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Ji-Su SHIM
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Kyung-Min AHN
			        		
			        		;
		        		
		        		
		        		
			        		Min-Hye KIM
			        		
			        		;
		        		
		        		
		        		
			        		Young-Joo CHO
			        		
			        		
		        		
		        		
		        		
		        		
		        			
			        		
			        		Author Information
			        		
		        		
		        		
			        		
			        		
			        			1. Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:CASE REPORT
 
        	
        	
            
            
            	- From:Allergy, Asthma & Respiratory Disease
	            		
	            		 2025;13(1):39-43
	            	
            	
 
            
            
            	- CountryRepublic of Korea
 
            
            
            	- Language:English
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	 Symmetric drug-related intertriginous and flexural exanthema (SDRIFE) is a rare drug-induced skin reaction characterized by distinctive rashes. It presents as sharply demarcated erythema in “V” shape on the flexural areas such as the buttocks and the groin. Additionally, it can affect other flexural regions such as the axillae, popliteal fossae, and antecubital fossae. SDRIFE typically occurs within a few days following systemic drug exposure, without prior cutaneous sensitization. It is generally associated with a favorable prognosis with no systemic involvement. Consequently, treatment usually involves discontinuation of the offending drug and symptomatic management with antihistamines, with systemic corticosteroids rarely necessary. Herein, we report a case of severe SDRIFE that developed six weeks after denosumab administration and required long-term systemic corticosteroids.